Related Experiment Video
Updated: Apr 14, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
19.1K
Systemic lupus erythematosus and thrombosis
Mario Bazzan1, Antonella Vaccarino1, Fabio Marletto1
1Haematology and Thrombosis Unit, CMID Department, San Giovanni Bosco Hospital, Piazza Donatore di Sangue 3, 10154 Turin, Italy.
Thrombosis Journal
|April 25, 2015
Summary
Systemic Lupus Erythematosus (SLE) increases the risk of dangerous blood clots. This risk is higher with antiphospholipid antibodies (aPL) and other factors, impacting patient quality of life.
Area of Science:
- Rheumatology
- Immunology
- Hematology
Background:
- Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations.
- SLE is an established independent risk factor for arterial and venous thrombotic events.
- The risk of thrombosis in SLE patients is elevated compared to the general population, particularly with co-existing risk factors.
Purpose of the Study:
- To investigate the prevalence and characteristics of thrombotic events in Systemic Lupus Erythematosus (SLE) patients.
- To understand the heightened risk of thrombosis in SLE, especially in the presence of antiphospholipid antibodies (aPL).
- To highlight the clinical significance and challenges of managing thrombosis in SLE patients.
Main Methods:
- Review of existing literature on SLE and thrombotic events.
- Analysis of cohort characteristics, laboratory assays, and clinical data.
- Comparison of thrombosis risk between SLE patients and the general population.
Main Results:
- SLE patients exhibit a higher prevalence of thrombotic events than healthy individuals.
- The association of SLE with antiphospholipid antibodies (aPL) significantly increases thrombotic event rates.
- Variability in study methodologies and populations complicates definitive conclusions.
Conclusions:
- Systemic Lupus Erythematosus (SLE) poses a significant, potentially life-threatening risk for thrombotic events.
- Antiphospholipid antibodies (aPL) are a critical factor exacerbating thrombosis risk in SLE.
- Effective management of thrombosis is crucial for improving outcomes and quality of life in SLE patients.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
724
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
724
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:24Nephrotic Syndrome I : Introduction
1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
445
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
445
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471